RE:RE:RE:RE:Re: Q3 update
I would certainly agree that the general content and quality of DME's press releases continues to disappoint (though it felt like things had improved there a bit for a while). Many companies with lower market caps and less cash seem able to engage investor relations firms that (apparently) do a much better job helping the companies generate better/clearer content.
Not to pile on, but I seem to remember being somewhat surprised in the latest financial statements that marketing expenses had been as high as they were. DME certainly needs stronger IR more than it needs strong marketing right now. I'm not sure why a development-stage company like DME (which will be selling a commodity rather than a branded product) really needs to have been spending meaningful amounts of scarce capital on marketing. (I used to see a fair amount of DME banner ads (which I'm sure cost $) here at Stockhouse and elsewhere, but fortunately not so much lately). Perhaps this largely reflects the cost of the periodic interviews with Ellis Martin, etc. - while I apprecate the depth/breadth of information that comes out of these interviews, I wouldn't want the company to spend a lot of money on that kind of thing. Then again, if those interviews helped get the word out about DME to an extent that helped us achieve the warrant exercise triggers, maybe that was a worthy "marketing" expense after all...though I don't see why we'd need it to continue.
In any case, it again all comes back to getting the initial processing facility online. If and when that happens, there will be plenty of validation about execution and resulting cash flows to fix things like DME's investors relations matters. Another day closer now...